National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, People's Republic of China.
Beijing Institute of Drug Metabolism, Beijing, People's Republic of China.
Int J Nanomedicine. 2024 Aug 6;19:8029-8042. doi: 10.2147/IJN.S464720. eCollection 2024.
Heterologous immunization using different vaccine platforms has been demonstrated as an efficient strategy to enhance antigen-specific immune responses. In this study, we performed a head-to-head comparison of both humoral and cellular immune response induced by different prime-boost immunization regimens of mRNA vaccine and adjuvanted protein subunit vaccine against varicella-zoster virus (VZV) in middle-aged mice, aiming to get a better understanding of the influence of vaccination schedule on immune response.
VZV glycoprotein (gE) mRNA was synthesized and encapsulated into SM-102-based lipid nanoparticles (LNPs). VZV-primed middle-aged C57BL/6 mice were then subjected to homologous and heterologous prime-boost immunization strategies using VZV gE mRNA vaccine (RNA-gE) and protein subunit vaccine (PS-gE). The antigen-specific antibodies were evaluated using enzyme-linked immunosorbent assay (ELISA) analysis. Additionally, cell-mediated immunity (CMI) was detected using ELISPOT assay and flow cytometry. Besides, in vivo safety profiles were also evaluated and compared.
The mRNA-loaded lipid nanoparticles had a hydrodynamic diameter of approximately 130 nm and a polydispersity index of 0.156. Total IgG antibody levels exhibited no significant differences among different immunization strategies. However, mice received 2×RNA-gE or RNA-gE>PS-gE showed a lower IgG1/IgG2c ratio than those received 2×PS-gE and PS-gE> RNA-gE. The CMI response induced by 2×RNA-gE or RNA-gE>PS-gE was significantly stronger than that induced by 2×PS-gE and PS-gE> RNA-gE. The safety evaluation indicated that both mRNA vaccine and protein vaccine induced a transient body weight loss in mice. Furthermore, the protein vaccine produced a notable inflammatory response at the injection sites, while the mRNA vaccine showed no observable inflammation.
The heterologous prime-boost strategy has demonstrated that an mRNA-primed immunization regimen can induce a better cell-mediated immune response than a protein subunit-primed regimen in middle-aged mice. These findings provide valuable insights into the design and optimization of VZV vaccines with the potentials to broaden varicella vaccination strategies in the future.
使用不同的疫苗平台进行异源免疫已被证明是增强抗原特异性免疫应答的有效策略。在这项研究中,我们对头对头比较了 mRNA 疫苗和佐剂蛋白亚单位疫苗对水痘带状疱疹病毒(VZV)在中年小鼠中诱导的体液和细胞免疫应答,旨在更好地了解疫苗接种方案对免疫应答的影响。
合成 VZV 糖蛋白(gE)mRNA 并包封在基于 SM-102 的脂质纳米颗粒(LNPs)中。然后,用 VZV gE mRNA 疫苗(RNA-gE)和蛋白亚单位疫苗(PS-gE)对 VZV 预致敏的中年 C57BL/6 小鼠进行同源和异源初免-加强免疫策略。使用酶联免疫吸附测定(ELISA)分析评估抗原特异性抗体。此外,通过 ELISPOT 测定和流式细胞术检测细胞介导的免疫(CMI)。此外,还评估和比较了体内安全性概况。
负载 mRNA 的脂质纳米颗粒的水动力学直径约为 130nm,多分散指数为 0.156。不同免疫策略之间总 IgG 抗体水平没有显著差异。然而,接受 2×RNA-gE 或 RNA-gE>PS-gE 的小鼠 IgG1/IgG2c 比值低于接受 2×PS-gE 和 PS-gE>RNA-gE 的小鼠。2×RNA-gE 或 RNA-gE>PS-gE 诱导的 CMI 反应明显强于 2×PS-gE 和 PS-gE>RNA-gE 诱导的 CMI 反应。安全性评估表明,mRNA 疫苗和蛋白疫苗均导致小鼠短暂体重减轻。此外,蛋白疫苗在注射部位产生明显的炎症反应,而 mRNA 疫苗无可见炎症。
异源初免-加强策略表明,在中年小鼠中,mRNA 初免免疫方案可诱导比蛋白亚单位初免方案更好的细胞介导免疫应答。这些发现为 VZV 疫苗的设计和优化提供了有价值的见解,有望拓宽未来水痘疫苗接种策略。